Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.08 -0.02 (-1.82%) Market Cap: 276.01 Mil Enterprise Value: 161.16 Mil PE Ratio: 0 PB Ratio: 10.80 GF Score: 70/100

Adaptimmune Therapeutics PLC at Citi BioPharma Conference (Virtual) Transcript

Sep 09, 2020 / 12:00PM GMT
Release Date Price: $8 (+1.39%)
Mohit Bansal
Citigroup Inc., Research Division - Director and Analyst

Great. Thank you, everyone, for joining us today. My name is Mohit Bansal, and I'm one of the biotech analysts here at Citi, and I welcome you all for Citi's 15th Annual Biopharma Virtual Conference. And to kick off my sessions in this conference, we have -- we are pleased to have Adaptimmune management team joining us today. We are joined by Gavin Wood, the CFO; John Lunger, the Chief Patient Supply Officer; Mark Dudley, the SVP of Early stage Development, and also Elliot Norry, MD and Chief Medical Officer of the company. Thank you, all of you for joining us today.

Gavin Hilary James Wood
Adaptimmune Therapeutics plc - CFO

Thank you.

Elliot Norry
Adaptimmune Therapeutics plc - Senior VP & Chief Medical Officer

Thank you.

Questions & Answers

Mohit Bansal
Citigroup Inc., Research Division - Director and Analyst

Great. So Elliot, this has been a quite eventful year for Adaptimmune. You

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot